comparemela.com

Latest Breaking News On - Key service - Page 5 : comparemela.com

Transcripts For SFGTV Government Access Programming 20240713

We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So

California
United-states
Japan
Togo
Breast-cancer
California-national
Skin-cancer
Prostate-cancer
Health-service
Health-service-system
Service-system

Transcripts For SFGTV Government Access Programming 20240713

We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So

California
United-states
Japan
Togo
Breast-cancer
California-national
Skin-cancer
Prostate-cancer
Health-service
Health-service-system
Service-system

Transcripts For SFGTV Government Access Programming 20240713

We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So

California
United-states
Japan
Togo
Breast-cancer
California-national
Skin-cancer
Prostate-cancer
Health-service
Health-service-system
Service-system

Transcripts For SFGTV Government Access Programming 20240713

We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So

California
United-states
Japan
Togo
Breast-cancer
California-national
Skin-cancer
Prostate-cancer
Health-service
Health-service-system
Service-system

Transcripts For SFGTV Government Access Programming 20240713

Benefit is and what you get through the smile way benefit. So that is why there is the difference in the flyers. But we have been promoting these at the health fair. I actually helped two of your retirees in role at the health fair just recently. They were really excited to learn about the program and that was really the conversation that we had during the Health Affairs the next slide is what you are currently doing. You are promoting on your plan resource section the delta dental wellness highlight. So both of the flyers are on your website and you also have a smile way Program Section and it actually gives the instructions to members on how they can and role in the plan. And then what i didnt put on here, and im so sorry, but you did promote smile way. You have, both in the retiree and the active benefit guides for 2020. You have a paragraph and there is a smile way pattern on there. And also there is a little footer on the benefit summary page in case they didnt read the content. T

Georgia
United-states
Togo
London
City-of
United-kingdom
San-francisco
California
Vivian-liang
Jeff-cooper
Phil-ginsburg
Michelle-welsh-steve

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.